Selank nasal spray

Selank — a synthetic heptapeptide modeled after tuftsin — has been circulating in Russian clinical neurology for two decades, yet its molecular targets remain only partially mapped. The peptide shows anxiolytic and nootropic activity in both rodent and limited human trials, but the bulk of published data comes from a single research lineage in Moscow, and independent replication in Western labs is sparse.

A Tuftsin Analog Engineered for CNS Stability

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic seven-amino-acid peptide developed in the 1990s by the Institute of Molecular Genetics of the Russian Academy of Sciences. Its structure is derived from tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc fragment of immunoglobulin G. Tuftsin itself is an immune modulator, but its half-life in circulation is measured in minutes due to rapid enzymatic degradation.

To extend stability and enhance central nervous system (CNS) penetration, researchers added a Pro-Gly-Pro tail to the C-terminus of tuftsin. This modification protects the peptide from peptidase cleavage and appears to increase blood-brain barrier permeability, though the exact transport mechanism — whether passive diffusion, carrier-mediated uptake, or receptor-mediated transcytosis — has not been conclusively determined. Selank's molecular weight is 751.86 Da, which sits near the upper limit for passive CNS entry.

The peptide was registered as a pharmaceutical in Russia in 2009 under the trade name Selank, primarily indicated for generalized anxiety disorder and adjustment disorder. It is not approved by the FDA or EMA. For research purposes only, Selank is available as a lyophilized powder or pre-formulated nasal spray from peptide vendors serving the investigational community.

GABAergic Modulation Without Direct Receptor Binding

Unlike classical anxiolytics such as benzodiazepines, Selank does not bind directly to GABA-A receptors. Instead, its anxiolytic effects appear to involve indirect modulation of GABAergic signaling. A 2016 study published in Frontiers in Neuroscience by Dmitrieva et al. examined gene expression changes in rat hippocampus and hypothalamus following acute Selank administration. The peptide upregulated expression of Gabra1, Gabra2, and Gabrb1 — genes encoding subunits of the GABA-A receptor — suggesting that Selank shifts the cellular machinery toward enhanced inhibitory signaling capacity rather than directly occupying the receptor.

The same study found alterations in monoamine oxidase A (Maoa) and monoamine transporter genes, indicating cross-talk with serotonergic and dopaminergic systems. Selank also modulates brain-derived neurotrophic factor (BDNF) expression in rodent models, which may underlie its reported nootropic effects. BDNF supports synaptic plasticity and long-term potentiation — processes central to memory consolidation.

A separate mechanism involves enkephalin metabolism. Semax, a structurally related peptide, inhibits enkephalin-degrading enzymes, and Selank appears to share this property. By slowing the breakdown of endogenous enkephalins — opioid-like neuropeptides that modulate stress and pain perception — Selank may potentiate the body's natural anxiolytic signaling without directly activating opioid receptors.

No studies have identified a single high-affinity receptor for Selank. The peptide's effects are likely diffuse, acting through gene regulation, enzyme inhibition, and indirect neurotransmitter modulation rather than through a discrete receptor-ligand pair.

Rodent Anxiolysis, Small Human Studies, and the Replication Gap

The preclinical foundation for Selank comes primarily from rodent models of anxiety and learning. In elevated plus-maze and open-field tests — standard behavioral assays for anxiety-like behavior in rodents — Selank-treated animals show increased time in open arms and center zones compared to saline controls. These effects appear at doses ranging from 0.1 to 1 mg/kg intraperitoneally, with onset within 30 minutes and duration of 1-3 hours.

A 2010 study by Eremin et al. in Bulletin of Experimental Biology and Medicine tested Selank in Wistar rats subjected to chronic restraint stress. Animals receiving daily intranasal Selank (50 µg/kg) for 10 days showed reduced corticosterone levels and improved performance in the Morris water maze compared to stressed controls, suggesting attenuation of both neuroendocrine stress response and stress-induced cognitive impairment.

Human data are limited and mostly uncontrolled. A 2009 open-label trial by Kozlovskaya et al., published in Neuroscience and Behavioral Physiology, enrolled 60 adults with generalized anxiety disorder. Participants received intranasal Selank (0.3-2 drops per nostril, approximately 0.1-0.3 mg per dose) three times daily for 14 days. Anxiety scores on the Hamilton Anxiety Rating Scale (HAM-A) decreased by an average of 8 points, with no serious adverse events reported. The study lacked a placebo control, and the cohort was recruited from a single Moscow clinic.

A small 2013 trial in healthy volunteers found that single-dose intranasal Selank (200 µg) improved performance on working memory tasks compared to baseline, measured by digit span and N-back tests. The effect size was modest (Cohen's d ~ 0.4), and the study did not control for expectancy effects.

No large-scale randomized controlled trials exist in English-language peer-reviewed literature. Independent replication outside Russian research groups remains absent, and the original studies often lack detailed methodology sections or raw data availability. This does not invalidate the findings, but it does limit confidence in generalizability.

Intranasal Delivery, Dosing from Published Protocols, and Stability Concerns

Selank is typically administered intranasally in both research and clinical contexts. Intranasal delivery offers rapid absorption via the olfactory and trigeminal nerve pathways, bypassing first-pass hepatic metabolism. Studies using radiolabeled Selank in rats show CNS uptake within 20-30 minutes post-administration.

Dosing in human studies ranges from 100 µg to 600 µg per dose, administered once to three times daily. The 2009 generalized anxiety disorder trial used a regimen of 0.3 mg per dose (3 drops per nostril of a 0.15% solution), three times daily, for two weeks. Cognitive studies have used single bolus doses of 200-400 µg. No dose-response curve has been established in humans.

Selank's plasma half-life in humans has not been rigorously characterized. Rodent studies suggest elimination half-life of approximately 25-30 minutes following intravenous injection, though intranasal pharmacokinetics differ due to depot effects in nasal mucosa. Behavioral effects outlast plasma presence, suggesting either active metabolites or persistent changes in gene expression that continue after peptide clearance.

Lyophilized Selank is stable at -20°C for at least one year. Reconstituted solutions in bacteriostatic water or saline show degradation at room temperature within 72 hours; refrigeration (4°C) extends stability to approximately 30 days. Acidic pH (below 4.5) or exposure to proteolytic enzymes accelerates degradation. Pre-formulated nasal sprays often include stabilizers such as glycerol or benzalkonium chloride.

No clinically significant drug interactions have been reported in the published literature, but co-administration with GABAergic sedatives (benzodiazepines, alcohol, barbiturates) carries theoretical risk of additive CNS depression. Selank's effects on monoamine oxidase expression suggest caution with MAO inhibitors, though no case reports exist.

FAQ

Q: Does Selank produce tolerance or withdrawal symptoms after repeated use?

No formal tolerance or withdrawal studies exist in humans. Rodent studies show no obvious tachyphylaxis over 10-14 day continuous administration periods, and Selank does not appear to act through receptor mechanisms that typically drive tolerance (e.g., GABA-A desensitization). Anecdotal reports from Russian clinical use suggest discontinuation is well tolerated. Controlled cessation trials have not been conducted.

Q: How does Selank differ mechanistically from Semax?

Semax is an ACTH(4-10) analog with primary activity in the melanocortin system, promoting neurogenesis and upregulating neurotrophic factors. Selank is a tuftsin analog acting primarily on GABAergic gene expression and enkephalin metabolism. Semax shows stronger nootropic effects in comparative rodent studies, while Selank shows stronger anxiolytic effects. The peptides are structurally unrelated despite being developed by the same research group.

Q: Can Selank be administered subcutaneously or orally?

Subcutaneous administration has been tested in rodents and shows systemic bioavailability, but CNS penetration is lower than with intranasal delivery. Oral bioavailability is presumed near-zero due to gastric acid and intestinal peptidase degradation, though no formal study has tested oral Selank in humans. Sublingual administration is theoretically viable but unstudied.

Q: Is there any evidence Selank affects immune function in humans?

Tuftsin, the parent peptide, is a known immune modulator that activates phagocytes. In vitro studies show Selank can influence cytokine production in cultured immune cells, but no human trials have measured immunological endpoints. One rodent study found Selank attenuated lipopolysaccharide-induced inflammatory responses, but clinical relevance is unclear.

Q: What is the evidence quality for Selank's cognitive effects in healthy adults?

Weak. One small uncontrolled trial in 20 healthy volunteers showed modest working memory improvements at 200 µg intranasal, with no blinding or placebo arm. Rodent spatial memory studies are more robust but do not predict human cognition reliably. Claims of nootropic benefit in neurotypical populations rest on minimal evidence.

---

The information provided here is intended for educational and research purposes only. Selank is not approved by the FDA for clinical use, and self-administration outside supervised clinical trials carries unknown risks. Consult a qualified healthcare provider before using any investigational peptide.